Seroatlas · Human Serome Atlas

AVP

Vasopressin-neurophysin 2-copeptin

Also known as: ADH, ARVP, NEU2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P01185
Gene
AVP
Ensembl
ENSG00000101200
Chromosome
20
Canonical length
164 aa
Protein class
Disease related genes, Human disease related genes, Predicted secreted proteins
Secretome location
Secreted to blood

OverviewNCBI Gene

This gene encodes a member of the vasopressin/oxytocin family and preproprotein that is proteolytically processed to generate multiple protein products. These products include the neuropeptide hormone arginine vasopressin, and two other peptides, neurophysin 2 and copeptin. Arginine vasopressin is a posterior pituitary hormone that is synthesized in the supraoptic nucleus and paraventricular nucleus of the hypothalamus. Along with its carrier protein, neurophysin 2, it is packaged into neurosecretory vesicles and transported axonally to the nerve endings in the neurohypophysis where it is either stored or secreted into the bloodstream. The precursor is thought to be activated while it is being transported along the axon to the posterior pituitary. Arginine vasopressin acts as a growth factor by enhancing pH regulation through acid-base transport systems. It has a direct antidiuretic action on the kidney, and also causes vasoconstriction of the peripheral vessels. This hormone can contract smooth muscle during parturition and lactation. It is also involved in cognition, tolerance, adaptation and complex sexual and maternal behaviour, as well as in the regulation of water excretion and cardiovascular functions. Mutations in this gene cause autosomal dominant neurohypophyseal diabetes insipidus (ADNDI). This gene is present in a gene cluster with the related gene oxytocin on chromosome 20. [provided by RefSeq, Nov 2015]

Canonical amino-acid sequenceUniProt

164 residues, UniProt reviewed canonical sequence.

>P01185|AVP
     1  MPDTMLPACF LGLLAFSSAC YFQNCPRGGK RAMSDLELRQ CLPCGPGGKG RCFGPSICCA
    61  DELGCFVGTA EALRCQEENY LPSPCQSGQK ACGSGGRCAA FGVCCNDESC VTEPECREGF
   121  HRRARASDRS NATQLDGPAG ALLLRLVQLA GAPEPFEPAQ PDAY

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against AVP can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Secreted
Secreted
Yes
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.46
Highest tissue expression
4,348 nTPM

Expression across tissuesHPA

Tissue

  • hypothalamus: 4,348 nTPM
  • midbrain: 13 nTPM
  • pituitary gland: 5.8 nTPM
  • hippocampal formation: 2.6 nTPM
  • basal ganglia: 1.7 nTPM
  • skin: 1.5 nTPM

Single-cell type

  • other brain neurons: 757 nCPM
  • hematopoietic stem cells: 613 nCPM
  • thymocytes: 129 nCPM
  • late spermatids: 46 nCPM
  • oocytes: 14 nCPM
  • epididymal efferent duct absorptive cells: 11 nCPM

Immune cell

  • eosinophil: 2.8 nTPM
  • T-reg: 0.5 nTPM
  • naive CD4 T-cell: 0.1 nTPM
  • naive CD8 T-cell: 0.1 nTPM
  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM

Brain region

  • hypothalamus: 15,977 nTPM
  • cerebral cortex: 210 nTPM
  • basal ganglia: 50 nTPM
  • amygdala: 17 nTPM
  • cerebellum: 2.9 nTPM
  • hippocampal formation: 2.6 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about AVP.

Disease | AllUniProt

Conditions AVP is implicated in, by any mechanism.

  • Diabetes insipidus, neurohypophyseal (NDI) MIM:125700

Disease | GeneticClinVar

36 pathogenic / likely-pathogenic of 152 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

  • Neurohypophyseal diabetes insipidus
  • AVP-related disorder
  • Diabetes insipidus, neurohypophyseal, autosomal recessive
  • Inborn genetic diseases

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.45
gnomAD pLI
0.07
gnomAD missense Z
1.05
DepMap mean gene effect
-0.11
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads AVP as an antibody target. Whether an autoantibody or antibody against AVP could matter depends on whether native AVP is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

AVP is annotated as secreted, so native AVP circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label AVP as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/AVP. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...